Mogamulizumab in patients with mycosis fungoides/Sézary syndrome: Translational data results from the MOGA-2MG-Q4W Phase 2, open-label, multicenter, single-arm study assessing a 4-weekly dosing schedule

IF 7.1 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2025-10-01 DOI:10.1016/j.ejca.2025.115851

Christiane Querfeld, Julia Scarisbrick, Oleg Akilov, Martine Bagot, Raul Cordoba, Richard Cowan, Alejandro Martıń Garcıá-Sancho, Larisa J. Geskin, Auris O. Huen, Stephen Morris, Pablo L. Ortiz-Romero, Lauren C. Pinter-Brown, Ramon M. Pujol, Pietro Quaglino, Nakhle S. Saba, Yi Liu, Henry Zhao, Payal Arora, Youn H. Kim

引用次数: 0

查看原文本刊更多论文

Mogamulizumab用于蕈样真菌病/ ssamzary综合征患者：MOGA-2MG-Q4W 2期，开放标签，多中心，单组研究，评估4周给药计划的转化数据结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.